Human Anti-Alpha-Synuclein Antibodies.
United States Patent Application; United States Patent Application 20110300077; 2011 Dec 8; DOI: y2011/0300077.html..
The acute inflammatory response to intranigral a-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation.
Journal of Neuroinflammation; 2011, 8:166.
The fusogenic tilted peptide (67–78) of α-synuclein is a cholesterol binding domain.
Biochimica et Biophysica Acta (BBA) – Biomembranes; Volume 1808, Issue 10, 2011 October, Pages 2343–2351.
Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein.
European Patent Application; European Patent Application EP2366714; 2011 Sept. 21.
Quantitative, Label-Free Detection of the Aggregation of α-Synuclein Using Microcantilever Arrays Operated in a Liquid Environment..
Journal of Sensors; http://dx.doi.org/10.1155/2012/874086.
PPMI Parkinson’s Progression Monitoring Initiative : CSF α-synuclein interlaboratory study.
Parkinson ‘s Progession Markers Initiative; 2011 July 7 PPMI – SYN – RR-1.
Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of α-synuclein in a cellular model of Parkinson's disease.
Neurochemistry International; Volume 58, Issue 7, June 2011, Pages 785–793 DOI: 10.1016/j.neuint.2011.03.004.
PAMAM G4 dendrimers affect the aggregation of α-synuclein.
International Journal of Biological Macromolecules; Volume 48, Issue 5, 2011 June 1, Pages 742–746; DOI: 10.1016/j.ijbiomac.2011.02.021..
Molecular Basis for the Glycosphingolipid-Binding Specificity of α-Synuclein: Key Role of Tyrosine 39 in Membrane Insertion.
Journal of Molecular Biology; Volume 408, Issue 4, 13 May 2011, Pages 654–669; DOI: 10.1016/j.bbr.2011.03.031.
Role of Matrix Metalloproteinase 3-mediated α-Synuclein Cleavage in Dopaminergic Cell Death.
J Biol Chem.; 2011 Apr 22;286(16):14168-77. Epub 2011 Feb 17..